抗代谢药物与包裹性囊状滤过泡  

Antimatabolite medicines and encapsulated filtering bleb

作　　者：余晓临[1] 杨国华[1] 陈静琪[1] 董仰增[1] 万光明[1] 

机构地区：[1]河南省眼科研究所

出　　处：《中国实用眼科杂志》1997年第4期232-235,共4页Chinese Journal of Practical Ophthalmology

摘　　要：为了探讨抗代谢药物对青光眼小梁切除术后包裹性囊状滤过泡形成的影响，本文分别对５０眼术中应用丝裂霉素Ｃ（ＭＭＣ）和４０眼术后结膜下注射５—氟尿嘧啶（５－Ｆｕ）的难治性青光眼进行分析。术后６个月，ＭＭＣ组手术成功率８６％；５－Ｆｕ组成功率８２．５％。包裹性囊状滤过泡的发生率，ＭＭＣ组１６％；５－Ｆｕ组１０％。结果表明，上述药物能明显减少滤过泡的瘢痕化，但不能减少包裹性囊状滤过泡的发生。男性、青少年性青光眼和以角膜缘为基底的结膜瓣发生率较高。The study was to determine efficacy of antimatabolite medicines on encapsulated filtering bleb formation after trabeculectomy.We applied mitomycin C(MMC)to 50 eyes intraoperatively and 5-fluorouracil(5 Fu)to 40 eyes postoperatively,all these eyes are refractory glaucoma.After 6 months of following up,success rate is 86% in MMC group,and 82 5% in 5-Fu group,the encapsulated filtering bleb occuring rate is 16% in MMC group,10% in 5-Fu group.This study gave proof that these antimatabolite medicines can prevent obviously scarring of filtering bleb,but it cant reduce the occuring rate of encapsulated filtering bleb.Male,juvenile and conjunctival limbus based flap may be three risk factors for encapsulated filtering bleb formation.

关 键 词：小梁切除术 囊状滤过泡 青光眼 抗代谢药 

分 类 号：R775.05[医药卫生—眼科] R977[医药卫生—临床医学]